{"id":1690,"date":"2022-03-24T21:05:35","date_gmt":"2022-03-24T21:05:35","guid":{"rendered":"https:\/\/linksus.net\/everythingals-mitsubishi-pharma-join-to-create-digital-biomarkers-als-news-today\/"},"modified":"2022-03-24T21:05:35","modified_gmt":"2022-03-24T21:05:35","slug":"everythingals-mitsubishi-pharma-join-to-create-digital-biomarkers-als-news-today","status":"publish","type":"post","link":"https:\/\/linksus2.linksus.net\/index.php\/2022\/03\/24\/everythingals-mitsubishi-pharma-join-to-create-digital-biomarkers-als-news-today\/","title":{"rendered":"EverythingALS, Mitsubishi Pharma Join to Create Digital Biomarkers – ALS News Today"},"content":{"rendered":"

\"\"
Get regular updates to your inbox.
by \t\t\t\t\t\t\t \t\t\t\t\t\t\t\tLindsey Shapiro PhD<\/a> \t\t\t\t\t\t\t<\/span> \t\t\t\t\t\t\t|<\/span> \t\t\t\t\t\t\tMitsubishi Tanabe Pharma America<\/a> (MTHA) has joined EverythingALS<\/a>\u2019s consortium to accelerate the development of new digital biomarkers for amyotrophic lateral sclerosis<\/a> (ALS).
While MTHA will provide support and funding for the project, the company will also have access to any generated data, which may help it advance its own clinical trials for ALS therapies.
\u201cWe are excited to participate in what we think is a new paradigm for successful drug development by building up digital biomarkers in ALS in collaboration with the ALS community,\u201d Yasutoshi Kawakami, president of MTHA, said in a press release<\/a>.
Biomarkers can serve several purposes including aiding in disease diagnosis and predicting outcomes. Digital biomarkers can take the form of digital devices, such as smartphones, computers, or watches to monitor for biological changes.
Consistent with its mission to use technology to support the care and treatment of people with ALS, EverythingALS is focused on developing new ALS digital biomarkers.
\u201cAfter my husband passed away from ALS in 2019, I was motivated to help in the pursuit and discovery of new digital biomarkers for ALS,\u201d said Indu Navar, CEO and co-founder of EverythingALS, a U.S. nonprofit that is part of the Peter Cohen Foundation.
Last year, it collaborated with Modality.ai to develop<\/a> a web-based computer program that uses audio and video recordings to monitor ALS progression through artificial intelligence (AI). The program is designed to identify speech problems, which are often among the first symptoms to emerge in ALS, and the\u00a0data can be collected at home on any computer device. EverythingALS hopes the program can be used for early detection and to accurately predict prognosis.
\u201cThrough my ALS and high-tech connections, I was able to recruit a professional team with incredible direct experience with this disease and ties within the ALS community, to help support the world\u2019s largest citizen-based, patient-centric ALS speech study as one of our first missions,\u201d Navar said.
More than 700 patients have been recruited to participate in the study so far, and early results show the program can identify significant differences in speech between healthy controls, pre-symptomatic patients, and symptomatic patients.\u00a0Adult ALS patients and healthy volunteers are still being recruited<\/a>.
\u201c[EverythingALS] is well positioned to transform ALS research through direct patient involvement and remote data collection,\u201d said James Berry, MD, an EverythingALS scientific advisory board member and ALS division chief at Massachusetts General Hospital.
\u201cThe speed with which EverythingALS has been able to recruit hundreds of participants in what has become the world\u2019s largest AI-empowered speech study of people with ALS has vastly exceeded everyone\u2019s expectations of what can be achieved,\u201d Berry said.
EverythingALS is also collaborating with Microsoft to develop a model that predicts ALS based on people\u2019s interactions with search engines (e.g. Google, Bing). Those interested in participating can contact the company here<\/a>.
Meanwhile, MTHA\u2019s oral formulation of edaravone, a potential ALS therapy, is currently under priority review<\/a>\u00a0for possible approval with the U.S. Food and Drug Administration.
Get regular updates to your inbox.
3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com<\/a>
Email: [email protected]<\/span><\/a>
Phone: 1-800-936-1363<\/a>
This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.<\/p>\n

source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Get regular updates to your inbox.by Lindsey Shapiro PhD | March 3, 2022 Mitsubishi Tanabe Pharma America (MTHA) has joined EverythingALS\u2019s consortium to accelerate the development of new digital biomarkers for amyotrophic lateral sclerosis (ALS).While MTHA will provide support and funding for the project, the company will also have access to any generated data, which […]<\/p>\n","protected":false},"author":869,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[],"tags":[],"_links":{"self":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts\/1690"}],"collection":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/users\/869"}],"replies":[{"embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/comments?post=1690"}],"version-history":[{"count":0,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts\/1690\/revisions"}],"wp:attachment":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/media?parent=1690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/categories?post=1690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/tags?post=1690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}